Pekka Mattila

Pekka is a co-founder and CEO of Desentum, a clinical-stage biotech company developing novel immunotherapies to treat allergies. Pekka has extensive experience of managing biotech companies, turning innovation into profitable business and of international transactions in the biotech field. Prior to founding Desentum, he was the co-founder of a Finnish biotech company Finnzymes and acted as its CEO for 25 years until 2010, when the company was acquired by Thermo Fisher Scientific.

In addition to TILT Biotherapeutics, Pekka is currently a board member in other biotechs including Aiforia, Medix Group and Mobidiag. Pekka holds a M.Sc. degree from Helsinki University of Technology in biochemistry, biotechnology and microbiology. Starting 2020 Pekka joined TILT Biotherapeutics as a board member and will apply his expertise for overseeing corporate governance, development and business activities.